Risk factors of temperature increase after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy

Hui-Xia Kang; Jun-Ying Ma; Yan-Yan Su; Shan Kang; Bao-Jie Feng; Xiao-Bei Feng; Xu-Sha Wang; Yun-Yun Lu

doi:10.3389/fonc.2023.1120499

Risk factors of temperature increase after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy

Front Oncol. 2023 Mar 22:13:1120499. doi: 10.3389/fonc.2023.1120499. eCollection 2023.

Authors

Hui-Xia Kang¹, Jun-Ying Ma¹, Yan-Yan Su¹, Shan Kang¹, Bao-Jie Feng¹, Xiao-Bei Feng¹, Xu-Sha Wang¹, Yun-Yun Lu¹

Affiliation

¹ Department of Gynecology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Abstract

Background: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the standard treatment for patients with peritoneal cancer (PC). Following CRS-HIPEC, patients may also face risks caused by whole body hyperthermia. This study analyzed the incidence of temperature increases following CRS-HIPEC and identified the attendant risk factors.

Methods: A retrospective analysis was carried out among 458 patients who received CRS-HIPEC at the Fourth Hospital of Hebei Medical University between August 2018 and January 2021. The patients were divided into two groups according to post-HIPEC axillary temperature (≥38°C), with the demographics and the laboratory test results subsequently analyzed and compared, and the risk factors pertaining to temperature increases analyzed using univariate and multivariate logistic regression.

Results: During CRS-HIPEC, 32.5% (149/458) of the patients with a temperature increase had an axillary temperature of not lower than 38°C, and 8.5% (39/458) of the patients with hyperpyrexia had an axillary temperature of not lower than 39°C. Female gender, gynecological malignancies, type of chemotherapy drug, increased postoperative neutrophil percentage, and a sharp drop in postoperative prealbumin were associated with the incidence of a temperature increase and axillary temperatures of >38°C. Among these factors, the type of chemotherapy drug was identified as an independent risk factor for a temperature increase during CRS-HIPEC.

Conclusion: By determining the risk factors pertaining to temperature increases during CRS-HIPEC, medical staff can identify the attendant risks among the patients and thus take preventive measures in a timely manner to maintain the patient's body temperature at a stable level. This suggests that further clinical research should be conducted to build a risk-prediction model for temperature increases following CRS-HIPEC.

Keywords: CRS; HIPEC; analysis; risk factors; temperature increase.